MarketBeat
08 Aug 2026, 05:04 UTC · 4h ago
Emergent Biosolutions Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
08 Aug 2026, 05:04 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
6 claims · each scored for market impact
Emergent Biosolutions lowered its full-year 2026 revenue guidance from $720–$760 million to $645–$675 million. — A significant downward revision in top-line growth typically triggers a negative price reaction as it signals deteriorating fundamentals.
-0.80The company recorded a non-cash impairment charge of approximately $191 million related to the NARCAN asset group due to competitive and pricing pressures. — Large impairments indicate a permanent write-down in the value of a core asset, signaling diminished future cash flows from a primary product.
-0.60Increased competition and aggressive pricing in the naloxone market are expected to weigh on NARCAN sales. — Market share erosion and price compression in a lead commercial product threaten long-term margins and revenue stability.
-0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Second-quarter revenue ($234 million) and adjusted EBITDA ($97 million) both exceeded prior guidance and analyst consensus. — Strong short-term execution and beats on key metrics provide a positive offset to the lowered long-term outlook.
+0.40Which stocks this story touches
Strong Q2 results and medical countermeasure growth are offset by a lowered full-year guidance, a $191 million impairment charge, and pricing pressure for NARCAN.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
MarketBeat
2h ago
